Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports

Group 1 - Eli Lilly and Company plans to invest $3 billion in China over the next decade to develop production capacity for its experimental type-2 diabetes and obesity treatment, orforglipron [1] - The company submitted a marketing application for orforglipron to China's drug regulator at the end of 2025 and aims to establish a localized manufacturing and supply system for oral solid dosage forms [1] - Eli Lilly is part of a trend among Western healthcare firms investing in manufacturing in China, following companies like Haleon, while others like Bristol Myers Squibb are divesting from the region [2] Group 2 - Eli Lilly develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3]